anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled drug containing 5,6-dimethyl-8-isopropenylbicyclo [4,4,0]decen-1-one-3, free from hormone-like side effects, and having mild effect to the skin and excellent remedying effect to pimple. CONSTITUTION:The titled dermatic drug for the remedy of pimple and having the above effects is prepared by compounding about 0.001-2wt% 5,6-dimethyl-8- isopropenylbicyclo[4,4,0]decen-1-one of formula in a drug for external application, e.g. cream, ointment, lotion, etc. The drug may contain, in addition to the above component, an antibacterial agent such as hexachlorophene, a drug such as vitamin A acid, a photosensitive compound, salicylic acid, zinc or its compound, lactic acid, etc., a kelatolytic agent, etc. to an extent not to lower the above effect. The rate of application depends upon the symptom, however, usually about 0.1mg-0.5g per dose and one-several doses a day of applying to the rash.
Ventricular fibrillation (VF) in acute myocardial infarction (AMI) is the main cause of deaths occurring in the acute phase of an ischemic event. Although it is known that genetics may play an important role in this pathology, the possible role of long non-coding RNAs (lncRNA) has never been studied. Therefore, the aim of this work is to study the expression of 10 lncRNAs in patients with and without VF in AMI. For this purpose, the expression of CDKN2B-AS1, KCNQ1OT1, LIPCAR, MALAT1, MIAT, NEAT1, SLC16A1-AS1, lnc-TK2-4:2, TNFRSF14-AS1, and UCA1 were analyzed. After the analysis and Bonferroni correction, the lncRNA CDKN2B-AS showed a statistical significance lower expression (P values of 2.514 x 10-5). In silico analysis revealed that six proteins could be related to the possible effect of lncRNA CDKN2B-AS1: AGO3, PLD4, POU4F1, ZNF26, ZNF326 and ZNF431. These in silico proteins predicted to have a low cardiac expression, although there is no literature indicating a potential relationship with VF in AMI. Thus, the lncRNA CDKN2B-AS1 shows a significant lower expression in patients with VF in AMI vs patients without VF in AMI. Literature data suggest that the role of CDKN2B1-AS is related to the miR-181a/SIRT1 pathway.
The invention discloses a traditional Chinese medicine composition for treating psoriasis, and a preparation method and application thereof, and belongs to the technical field of medicines. The Chinese medicinal composition comprises oral composition and topical composition, wherein the oral composition comprises Scutellariae radix, cortex Phellodendri, coptidis rhizoma, rhizoma Smilacis Glabrae, fructus Gardeniae, radix Gentianae, rhizoma Dioscoreae Septemlobae, herba Eupatorii, alismatis rhizoma, radix Sophorae Flavescentis, rhizoma Atractylodis, fructus forsythiae and cortex Erythrinae. The topical composition comprises Coptidis rhizoma, cortex Phellodendri, scutellariae radix, herba Siegesbeckiae herba, herba Hedyotidis Diffusae, rhizoma Smilacis Glabrae, radix Sophorae Flavescentis and rhizoma Atractylodis. The topical composition is applied to the affected skin surface during administration of the oral composition. After the oral composition and the external composition are combined, the symptoms of erythema, scaling, thickening and the like of psoriasis can be obviously relieved, the curative effect is obvious, and the external composition can cooperate with the oral composition to ensure that the oral composition has better treatment effect, and the oral composition and the external composition have synergistic effect. The traditional Chinese medicine composition has definite curative effect, low recurrence rate and small side effect, provides a favorable means for clinically treating psoriasis, and is convenient for large-scale popularization.
OBJECTIVE: Biological risk factors for cardiovascular disease may relate to poor treatment responsiveness in major depressive disorder (MDD). These factors encompass low-grade inflammation and autonomic dysregulation, as indexed by decreased heart rate variability (HRV) and increased heart rate (HR). This secondary analysis examined whether higher levels of inflammatory markers or autonomic alterations relate to lower responsiveness to cognitive behavioral therapy (CBT) among individuals with MDD.
METHODS: Eighty antidepressant-free patients with MDD were randomly assigned to 14 weeks of CBT or waitlist (WL). Potential biological moderators at study entry included HR and HRV (24-h, daytime, nighttime) and inflammatory markers such as C-reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Forty non-clinical controls were involved to verify biological alterations in MDD at study entry. Depressive symptoms were assessed at baseline and at the end of treatment.
RESULTS: Individuals with MDD exhibited reduced total 24-h HRV (i.e., triangular index) and daytime HRV (i.e., triangular index, HF-HRV, LF-HRV, RMSSD), as well as increased levels of inflammatory markers. Patients who received CBT exhibited stronger reductions in self- and clinician-rated depressive symptoms, compared to WL. False discovery rate-adjusted moderation analyses did not show overall moderating effects of biological measures on treatment responsiveness. However, higher CRP levels were specifically associated with poorer improvement in somatic depressive symptoms.
CONCLUSIONS: There was no overall evidence for a moderating role of inflammation or autonomic features in CBT responsiveness in MDD. Higher levels of CRP might, however, specifically be associated with less improvement in somatic depressive symptoms during CBT.
BACKGROUND: Understanding how patients' frailty and the physiological stress of surgical procedures affect postoperative outcomes may inform risk stratification of older patients undergoing surgery. The objective of the study was to examine the association of peri-operative frailty with mortality, 30-day readmission and days at home after non-cardiac surgical procedures of different physiological stress.
METHODS: This retrospective study used Medicare claims data from a 7.125% random sample of Medicare fee-for-service beneficiaries from 2015 to 2019 who were aged ≥ 65 years and underwent non-cardiac surgical procedure listed in the Operative Stress Score categories. The exposure of the study was claims-based frailty index (robust, < 0.15; pre-frail, 0.15 to < 0.25; mildly frail, 0.25 to < 0.35; and moderate-to-severely frail, ≥ 0.35) with Operative Stress Score categories being 1, very low stress to 5, very high stress. The primary outcome was all-cause mortality at 30 days and 365 days after the surgical procedure.
RESULTS: In total, 1,019,938 patients (mean (SD) age of 76.1 (7.3) years; 52.3% female; 16.8% frail) were included. The cumulative incidence of mortality generally increased with Operative Stress Score category, ranging from 5.0% (Operative Stress Score 2) to 24.9% (Operative Stress Score 4) at 365 days. Within each category, increasing frailty was associated with mortality at 30 days (hazard ratio comparing moderate-to-severe frailty vs. robust ranged from 1.59-3.91) and at 365 days (hazard ratio 1.30-4.04). The variation in postoperative outcomes by patients' frailty level was much greater than the variation by the operative stress category.
CONCLUSIONS: These results emphasise routine frailty screening before major and minor non-cardiac procedures and the need for greater clinician awareness of postoperative outcomes beyond 30 days in shared decision-making with older adults with frailty.
Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
PURPOSE:To enhance a diagnostic capability, by specifying a displaying range based on tomographic images and rotation-displaying inverted projection images within a specified range. CONSTITUTION:Upon completion of photographing, tomographic images are stored in an image storage 1 and necessary ones of the images in an image memory 2. Then, a reference tomographic image is extracted out of the ones in the image memory 2 and displayed on an image display 4. While being observed, this reference image is manipulated via a keyboard 6 to specify the range of an inverted tomographic image to be displayed. An inverted projection image is then displayed as an integrating image on the display 4 within a specified range by rotating a positioning device 7. The inverted projection image can be displayed over a 360 deg. range to give a clear display of a portion to be diagnosed.
OBJECTIVE: To investigate whether a previous cesarean section increases the risk of perioperative and postoperative complications during vaginal hysterectomy.
METHODS: A retrospective cohort study of women who had undergone a vaginal hysterectomy for benign indications between 2014 and 2019 was conducted, comparing patients with or without a previous cesarean section. Perioperative and postoperative complications during vaginal hysterectomy were assessed according to the Clavien-Dindo classification system within 30 days of surgery. Duration of surgery, estimated blood loss, and postoperative hospitalization days were also recorded. A two-sided P value of less than 0.05 was considered significant.
RESULTS: A total of 185 women were included, 25 (13.5%) patients had undergone a previous cesarean section (study group) and 160 (86.5%) had no history of cesarean section (comparison group). We found no significant differences in demographic and clinical characteristics as well as postoperative complications and interventions, duration of surgery, estimated blood loss, and postoperative hospitalization days (P > 0.05). However, patients who underwent two or more cesarean sections had a significantly (P = 0.01) higher rate and grade of complications during vaginal hysterectomy, compared with women with only one previous cesarean section. All women who underwent two or more cesarean sections had mild complications during vaginal hysterectomy (40% grade I and 60% grade II, P = 0.01).
CONCLUSION: Vaginal hysterectomy is a safe procedure with few severe complications, regardless of a previous cesarean section. More than one previous cesarean section may increase the risk of minor complications during a vaginal hysterectomy. Patients who underwent a previous cesarean section could be reassured that they do not face an increased risk of complications during a vaginal hysterectomy.
Surufatinib 300mg will be taken orally once daily continuously through a 28-day cycle of study treatment. After treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination. Patients with high risk of postoperative recurrence will receive 131I treatment. After 131I treatment, maintenance treatment with surufatinib will be determined according to the recurrence risk stratification.
A composition for treating hair includes an effective amount of a herbal extract extracted from Angelica and Astragali Radix. The herbal extract is prepared by adding water to these herbs in dried form, and heating the resulting liquid for 1 to 8 hours, at a temperature of about 90-200 degrees Celsius. An amine compound, preferably diethanol amine, or a combination of triethanol amine and dioctyl sodium sulfosuccinate, is added to the herbal extract. Benzoic acid, dissolved in ethanol, is also added to the herbal extract, together with water. The resulting solution is fermented between 12 to 24 hours, in an ultrasonic fermentation apparatus operating at about 15 KHz. A method for the treatment of hair loss includes applying to the scalp the above-described composition.
OBJECTIVES: I. Determine the response rate and median duration of response of interleukin-2 (IL-2) in patients with previously treated non-small cell lung cancer. II. Determine the median survival of patients treated with IL-2. III. Further delineate the toxicity of IL-2 in these patients.

OUTLINE: This is an open label study. Patients receive bolus interleukin-2 on days 1-5 and 8-12. The cycle repeats every 3 weeks. Patient response is evaluated after 2 cycles. Patients with stable disease, partial, or complete response may be treated with maintenance IL-2 for up to 4 additional cycles. Patient evaluation is performed after every 2 cycles. At this point, patients with stable or responding disease may be treated with IL-2 every 6 weeks until disease progression, intolerable toxic effects, or 2 cycles beyond complete response.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued.
Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
PURPOSE:To easily obtain Ca-P type apatite useful as a biomaterial, a filler, etc., in a short time by allowing a mixture of phosphoric acid with quick lime or slaked lime to react with an alkali agent under special conditions. CONSTITUTION:A soln. contg. phosphoric acid is mixed with quick lime or slaked lime while keeping pH<=7 until the molar ratio of Ca to P becomes 1. The resulting soln. is kept at >=40 deg.C and allowed to react with slaked lime, quick lime or a soluble Ca salt and an alkali agent while keeping pH<=10 until the molar ratio of Ca to P becomes 1.6. The soluble Ca salt is then added to regulate the molar ratio of Ca to P to 1.67, the alkali agent is continuously or intermittently added and Ca-P type apatite is produced at pH 9-11.
Participants will be randomized to receive multiple doses of one of different dose levels of VX-840. The dose levels will be determined based on the data from Part A.
The safety and effectiveness of Corlanor have been established in pediatric patients (age 6 months to less than 18 years old) and are supported by pharmacokinetic and pharmacodynamic trials and evidence from adequate and well-controlled trials of Corlanor in adult patients. The pediatric study included 116 patients in the following age groups: 17 patients in the 6 months to less than 12 months age group, 36 patients in the 1 year to less than 3 years age group, and 63 patients in the 3 years to less than 18 years age group [see Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.2)].

The safety and efficacy of Corlanor have not been established in patients less than 6 months of age.

Animal Data

Ivabradine given orally to juvenile rats from post-natal day (PND) 7 until PND 77 at 7.5, 15 and 30 mg/kg/day did not affect post-natal (pre-weaning) development and reproductive performance (post-weaning development). Similar to adult animals, ivabradine decreased heart rate dose-dependently, and increased heart weights at the highest dose administered. Ivabradine also decreased white blood cell counts (lymphocytes) at the highest dose administered. The decrease in white blood cell counts partially reversed within a 3-week recovery period. Exposures in male and female rats at the No Observed Adverse Effect Level (NOAEL) of 7.5 mg/kg/day, was approximately 3 and 8 times, respectively, steady state exposure associated with the highest received maintenance doses across age groups in pediatric patients (based on AUCs).
23.4% Sodium Chloride Injection, USP Additive Solution is administered intravenously only after addition to a larger volume of fluid.

The dose, dilution and rate of injection are dependent upon the individual needs of each patient. In solutions for total parenteral nutrition (TPN), 120 mEq of sodium/day (range: 75–180 mEq/day) is the recommended adult dosage, whereas the recommended dosage is 3–4 mEq/kg/day for preterm infants.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard unused portion.

Additives may be incompatible with the fluid dispensed from this container. Consult with pharmacist, if available. When admixing, use aseptic technique, mix thoroughly and do not store.
Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
The invention provides a method for controlling an injection device (5) with special guarantee of no wrong injection. Patient data (D) for a patient (2) to be treated are provided and an injection preparation (K) used in the injection device (5) is automatically identified by the injection device automatically reading a label (32) provided on a container (21) of the injection preparation (k). Furthermore, contraindications (G) for an identified injection preparation (K) are determined. The patient data (D) are compared with the any contraindication (G) that has been determined. At least one protective measure is adopted to prevent the injection when at least one contraindication (G) matches the patient data (D). According to another variant of the method, patient data (D) for a patient (2) to be treated and contraindications (G) for the injection preparations (K) available for a selection are established. The patient data (D) are compared with the contraindications (G), wherein at least one injection preparation (K) is suggested which contraindications (G) do not match the patient data (D).
Marked nausea and vomiting occur in almost all patients treated with cisplatin, and may be so severe that the drug must be discontinued. Nausea and vomiting may begin within 1 hour to 4 hours after treatment and last up to 24 hours. Various degrees of vomiting, nausea and/or anorexia may persist for up to 1 week after treatment. 

Delayed nausea and vomiting (begins or persists 24 hours or more after chemotherapy) has occurred in patients attaining complete emetic control on the day of cisplatin therapy. 

Diarrhea has also been reported. 

To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
BACKGROUND: Since primary membranous nephropathy is a heterogeneous disease with variable outcomes and multiple possible therapeutic approaches, all 13 Nephrology Units of the Italian region Emilia Romagna decided to analyze their experience in the management of this challenging glomerular disease.
METHODS: We retrospectively studied 205 consecutive adult patients affected by biopsy-proven primary membranous nephropathy, recruited from January 2010 through December 2017. The primary outcome was patient and renal survival. The secondary outcome was the rate of complete remission and partial remission of proteinuria. Relapse incidence, treatment patterns and adverse events were also assessed.
RESULTS: Median (IQR) follow-up was 36 (24-60) months. Overall patient and renal survival were 87.4% after 5 years. At the end of follow-up, 83 patients (40%) had complete remission and 72 patients (35%) had partial remission. Among responders, less than a quarter (23%) relapsed. Most patients (83%) underwent immunosuppressive therapy within 6 months of biopsy. A cyclic regimen of corticosteroid and cytotoxic agents was the most commonly used treatment schedule (63%), followed by rituximab (28%). Multivariable analysis showed that the cyclic regimen significantly correlates with complete remission (odds ratio 0.26; 95% CI 0.08-0.79) when compared to rituximab (p < 0.05).
CONCLUSIONS: In our large study, both short- and long-term outcomes were positive and consistent with those published in the literature. Our data suggest that the use of immunosuppressive therapy within the first 6 months after biopsy appears to be a winning strategy, and that the cyclic regimen also warrants a prominent role in primary membranous nephropathy treatment, since definitive proof of rituximab superiority is lacking.
Topical Pharyngeal anesthesia (TPA) is widely used as an adjunct to sedation during upper endoscopy. TPA improves patient tolerance and the ease of endoscopy.1 Methemoglobinemia and anaphylactic reactions are serious complications of such topical anaesthetic agents, as lidocaine, tetracaine, and benzocaine. Articaine is as a unique amide local anaesthetic that possesses both an amide and an ester linkage and this is of clinical significance in minimizing the risk of overdose (toxic reaction). In routine dental procedures, articaine is a superior anaesthetic to lidocaine. Also, in comparison to lidocaine articaine acts faster and its duration of action is shorter what may be an advantage in such relatively fast procedures as gastroscopy. Articaine have not been previously evaluated in pharyngeal anesthesia for upper endoscopy. The aim of this randomised double-blind placebo controlled study was to compare pharyngeal anesthesia with 4% articaine to placebo (Na0,9%) during gastroscopy in terms of benefit on patients' and endoscopists'satisfaction.
The AurkA serine/threonine kinase is a key regulator of cell division controlling mitotic entry, centrosome maturation, and chromosome segregation. The microtubule-associated protein TPX2 controls spindle assembly and is the main AurkA regulator, contributing to AurkA activation, localisation, and stabilisation. Since their identification, AurkA and TPX2 have been described as being overexpressed in cancer, with a significant correlation with highly proliferative and aneuploid tumours. Despite the frequent occurrence of AurkA/TPX2 co-overexpression in cancer, the investigation of their involvement in tumorigenesis and cancer therapy resistance mostly arises from studies focusing only on one at the time. Here, we review the existing literature and discuss the mitotic phenotypes described under conditions of AurkA, TPX2, or AurkA/TPX2 overexpression, to build a picture that may help clarify their oncogenic potential through the induction of chromosome instability. We highlight the relevance of the AurkA/TPX2 complex as an oncogenic unit, based on which we discuss recent strategies under development that aim at disrupting the complex as a promising therapeutic perspective.
Formulations and methods for transdermal drug delivery compositions that include synergistic combination of three pharmaceutical active ingredients (APIs), such as testosterone, anastrozole, and HCG are disclosed. TBTC of the present disclosure may be indicated for reducing symptoms of testosterone deficiency. Disclosed TBTC may include permeation enhancers that may improve penetration of testosterone, anastrozole, and HCG in human skin. Permeation enhancer compositions within TBTC may include oils from amazon rainforest such as Pracaxi oil,  Plukenetia volubilis  seed oil, Inaja oil, and Pataua oil, which includes behenic and oleic fatty acids that may provide penetration power. TBTC may include organic solvents as transdermal penetration enhancers. Additionally, TBTC may include physiological lipids, phospholipids, and one or more butters rich in linoleic acid and linolenic acid that may also provide penetration power with restorative benefits to the skin.